RU2005137361A - Блокаторы рецептора ангиотензина ii, предназначенные для предупреждения развития или прогрессирования обусловленного диабетом микрососудистого заболевания - Google Patents
Блокаторы рецептора ангиотензина ii, предназначенные для предупреждения развития или прогрессирования обусловленного диабетом микрососудистого заболевания Download PDFInfo
- Publication number
- RU2005137361A RU2005137361A RU2005137361/14A RU2005137361A RU2005137361A RU 2005137361 A RU2005137361 A RU 2005137361A RU 2005137361/14 A RU2005137361/14 A RU 2005137361/14A RU 2005137361 A RU2005137361 A RU 2005137361A RU 2005137361 A RU2005137361 A RU 2005137361A
- Authority
- RU
- Russia
- Prior art keywords
- angiotensin
- receptor blocker
- progression
- development
- diabetes
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 5
- 230000002265 prevention Effects 0.000 title 1
- 239000003087 receptor blocking agent Substances 0.000 claims 10
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 9
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 102000005862 Angiotensin II Human genes 0.000 claims 4
- 101800000733 Angiotensin-2 Proteins 0.000 claims 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 4
- 229950006323 angiotensin ii Drugs 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 210000003668 pericyte Anatomy 0.000 claims 3
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 239000005480 Olmesartan Substances 0.000 claims 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 2
- 229960000932 candesartan Drugs 0.000 claims 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 229960004563 eprosartan Drugs 0.000 claims 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 229960002198 irbesartan Drugs 0.000 claims 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 2
- 229960004773 losartan Drugs 0.000 claims 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 2
- 229960005117 olmesartan Drugs 0.000 claims 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000001474 proteinuria Diseases 0.000 claims 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 2
- 230000006950 reactive oxygen species formation Effects 0.000 claims 2
- 208000037905 systemic hypertension Diseases 0.000 claims 2
- 229960005187 telmisartan Drugs 0.000 claims 2
- 229960004699 valsartan Drugs 0.000 claims 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (11)
1. Способ предупреждения развития или прогрессирования обусловленного диабетом микрососудистого заболевания, заключающийся в том, что индивидууму, нуждающемуся в этом, вводят фармацевтически эффективное количество блокатора рецептора ангиотензина II.
2. Способ по п.1, в котором блокатор рецептора ангиотензина II представляет собой блокатор рецептора, который ингибирует в культуре перицитов внутриклеточное образование реакционноспособных видов кислорода, индуцируемое присутствием ангиотензина II в культуральной среде.
3. Способ по п.2, в котором блокатор рецептора ангиотензина II выбран из ряда, включающего кандесартан, эпросартан, ирбесартан, лосартан, олмесартан, телмисартан и валсартан.
4. Способ по п.1, в котором предупреждают развитие или прогрессирование диабетической ретинопатии.
5. Способ по п.1, в котором индивидуум подвержен одному или нескольким факторам риска возникновения диабета, повышенного уровня глюкозы в крови, протеинурии, повышенного уровня азота мочевины в крови, повышенного уровня креатинина в крови, микропротеинурии или системной гипертензии.
6. Способ скрининга блокаторов рецептора ангиотензина II, предупреждающих развитие или прогрессирование микрососудистого заболевания, связанного с диабетом, заключающийся в том, что
(а) обрабатывают клетки тканевой культуры перицитов ангиотензином II или оставляют без обработки в присутствии соединения, представляющего собой потенциальный блокатор рецептора ангиотензина II или без него,
(б) измеряют количество образовавшихся внутри клеток реакционноспособных видов кислорода и
(в) выявляют соединения, которые ингибируют внутриклеточное образование реакционноспособных видов кислорода, индуцированное присутствием ангиотензина II в культуральной среде.
7. Фармацевтическая композиция для предупреждения развития или прогрессирования микрососудистого заболевания, обусловленного диабетом, такого как диабетическая ретинопатия, содержащая фармацевтически эффективное количество блокатора рецептора ангиотензина II.
8. Применение блокатора рецептора ангиотензина II для приготовления фармацевтической композиции для предупреждения развития или прогрессирования микрососудистого заболевания, обусловленного диабетом, такого как диабетическая ретинопатия, у индивидуума, нуждающегося в этом.
9. Применение по п.8, где блокатор рецептора ангиотензина II представляет собой блокатор рецептора, который ингибирует в культуре перицитов внутриклеточное производство реакционноспособных видов кислорода, индуцируемое присутствием ангиотензина II в культуральной среде.
10. Применение по п.9, где блокатор рецептора ангиотензина II выбран из ряда, включающего кандесартан, эпросартан, ирбесартан, лосартан, олмесартан, телмисартан и валсартан.
11. Применение по п.8, где индивидуум подвержен одному или нескольким факторам риска возникновения диабета, повышенного уровня глюкозы в крови, протеинурии, повышенного уровня азота мочевины в крови, повышенного уровня креатинина в крови, микропротеинурии или системной гипертензии.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10319592A DE10319592A1 (de) | 2003-05-02 | 2003-05-02 | Behandlung von diabetischer Retinopathie mit Angiotensin II-Rezeptorblockern |
| DE10319592.0 | 2003-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005137361A true RU2005137361A (ru) | 2006-07-27 |
Family
ID=33305091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005137361/14A RU2005137361A (ru) | 2003-05-02 | 2004-04-30 | Блокаторы рецептора ангиотензина ii, предназначенные для предупреждения развития или прогрессирования обусловленного диабетом микрососудистого заболевания |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1622607A1 (ru) |
| JP (1) | JP2006525269A (ru) |
| KR (1) | KR20060009288A (ru) |
| CN (1) | CN1784225A (ru) |
| AU (1) | AU2004233597A1 (ru) |
| BR (1) | BRPI0409853A (ru) |
| CA (1) | CA2524248A1 (ru) |
| DE (1) | DE10319592A1 (ru) |
| MX (1) | MXPA05011760A (ru) |
| RU (1) | RU2005137361A (ru) |
| WO (1) | WO2004096211A1 (ru) |
| ZA (1) | ZA200508263B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7812770B2 (en) | 2006-08-29 | 2010-10-12 | Research In Motion Limited | Mobile wireless communications device including an electrically conductive, electrically floating element and related methods |
| WO2009087900A1 (ja) * | 2008-01-11 | 2009-07-16 | Daiichi Sankyo Company, Limited | 眼内血管透過性亢進を伴う疾患の予防または治療のための医薬 |
| JP5860210B2 (ja) * | 2010-12-07 | 2016-02-16 | 株式会社オフテクス | アンジオテンシンｉｉ受容体拮抗薬であるテルミサルタン及びロサルタンの少なくとも１種を有効成分とする涙液分泌促進用組成物、及びそれを含有する涙液分泌促進用経口投与用製剤 |
| KR102233673B1 (ko) * | 2016-01-27 | 2021-03-30 | 보령제약 주식회사 | 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| WO2002015935A1 (en) * | 2000-08-25 | 2002-02-28 | Takeda Chemical Industries, Ltd. | Fibrinogen lowering agents |
| US20020091082A1 (en) * | 2000-09-13 | 2002-07-11 | Aiello Lloyd P. | Methods of modulating symptoms of hypertension |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
-
2003
- 2003-05-02 DE DE10319592A patent/DE10319592A1/de not_active Withdrawn
-
2004
- 2004-04-30 MX MXPA05011760A patent/MXPA05011760A/es unknown
- 2004-04-30 EP EP04730529A patent/EP1622607A1/en not_active Withdrawn
- 2004-04-30 RU RU2005137361/14A patent/RU2005137361A/ru not_active Application Discontinuation
- 2004-04-30 KR KR1020057020840A patent/KR20060009288A/ko not_active Withdrawn
- 2004-04-30 BR BRPI0409853-6A patent/BRPI0409853A/pt not_active IP Right Cessation
- 2004-04-30 WO PCT/EP2004/004616 patent/WO2004096211A1/en not_active Ceased
- 2004-04-30 JP JP2006505345A patent/JP2006525269A/ja active Pending
- 2004-04-30 CA CA002524248A patent/CA2524248A1/en not_active Abandoned
- 2004-04-30 CN CNA200480011878XA patent/CN1784225A/zh active Pending
- 2004-04-30 AU AU2004233597A patent/AU2004233597A1/en not_active Abandoned
-
2005
- 2005-10-12 ZA ZA200508263A patent/ZA200508263B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0409853A (pt) | 2006-05-16 |
| ZA200508263B (en) | 2007-02-28 |
| MXPA05011760A (es) | 2006-01-26 |
| DE10319592A1 (de) | 2004-11-18 |
| CN1784225A (zh) | 2006-06-07 |
| KR20060009288A (ko) | 2006-01-31 |
| CA2524248A1 (en) | 2004-11-11 |
| WO2004096211A1 (en) | 2004-11-11 |
| AU2004233597A1 (en) | 2004-11-11 |
| JP2006525269A (ja) | 2006-11-09 |
| EP1622607A1 (en) | 2006-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2904447C (en) | Therapy for complications of diabetes | |
| US9387249B2 (en) | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone | |
| Rodgers et al. | Angiotensin II-receptor blockers: clinical relevance and therapeutic role | |
| JP2005533023A5 (ru) | ||
| WO2007098390A2 (en) | Method for treating resistant hypertension | |
| US20090221549A1 (en) | Antihypertensive therapy | |
| US20090221656A1 (en) | Drug Combinations | |
| Kosugi et al. | eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists | |
| RU2005137361A (ru) | Блокаторы рецептора ангиотензина ii, предназначенные для предупреждения развития или прогрессирования обусловленного диабетом микрососудистого заболевания | |
| EP3132803A2 (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| Kirch et al. | Comparison of angiotensin II receptor antagonists | |
| RU2007139928A (ru) | Производное бензимидазола и применение в качестве антагониста ангиотензина | |
| Martins-Oliveira et al. | Direct renin inhibition is not enough to prevent reactive oxygen species generation and vascular dysfunction in renovascular hypertension | |
| DK2919780T3 (en) | 1,3-Dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury | |
| Ishimitsu et al. | Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases | |
| Bucci et al. | ACE-inhibition ameliorates vascular reactivity and delays diabetes outcome in NOD mice | |
| Camarero et al. | Photoswitchable dynasore analogs to control endocytosis with light | |
| Unger | Pharmacological aspects of candesartan, an effective AT1-receptor blocker | |
| 전윤아 | Effects of Angiotensin Receptor Blocker and Dapagliflozin on Blood Pressure Control, Vascular and Renal Function | |
| Van de Wal et al. | Urinary albumin excretion and the renin–angiotensin system in cardiovascular risk management | |
| Small | Antihypertensive drugs | |
| Konoshita et al. | A CROSS-OVER COMPARISON OF ANTI-ALBUMINURIC EFFECTS AMONG 4 TYPES CALCIUM CHANNEL BLOCKERS ON CHRONIC KIDNEY DISEASE: PP. 33.310 | |
| Strauch et al. | NON-COMPLIANCE TO THERAPY AS A FREQUENT CAUSE OF RESISTANT HYPERTENSION–HOW COMMON AND HOW TO DETECT IT?: PP. 33.309 | |
| Águila et al. | CHANGES IN WAVE PULSE VELOCITY INSIDE A GROUP OF NON PREVIOUSLY TREATED HYPERTENSIVE PATIENTS: PP. 33.311 | |
| Montesinos et al. | Quantal release of catecholamines. A new target for-adrenergic antagonists. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090402 |